Gevo Insider Exercise and 10b5-1 Sales Reported by Director
Rhea-AI Filing Summary
Amorelli Angelo, a director of Gevo, Inc. (GEVO), reported stock option exercise and subsequent open-market sales. On 08/12/2025 the reporting person acquired 100,000 shares by exercising options at an exercise price of $0.67 per share. That same day the filing shows sales of 183,515 shares reported under a 10b5-1 plan at a weighted average price of $1.9484 per share, and on 08/13/2025 an additional 16,485 shares were sold at a weighted average price of $2.00 per share. After these transactions the reporting person beneficially owned 124,639 derivative-backed shares and 2,942 to 202,942 common shares depending on the line item reported in the filing.
Positive
- Reported exercise of options: 100,000 shares acquired at an exercise price of $0.67 on 08/12/2025.
- Sales were executed pursuant to a documented 10b5-1 trading plan adopted 12/03/2024, as disclosed in the filing.
Negative
- Open-market dispositions: 183,515 shares sold on 08/12/2025 at a weighted average price of $1.9484 per share.
- Additional disposition: 16,485 shares sold on 08/13/2025 at a weighted average price of $2.00 per share.
- After the transactions the reporting person’s direct common stock holdings reported on lines vary, showing potential reductions in direct beneficial ownership (e.g., down to 2,942 shares on one line).
Insights
TL;DR Insider exercised options for 100,000 shares then sold ~200,000 shares under a 10b5-1 plan, showing material insider liquidity.
The filing documents option exercise at $0.67 for 100,000 shares on 08/12/2025 and multiple open-market sales totaling 200,000 shares across 08/12/2025 and 08/13/2025 at weighted average prices of $1.9484 and $2.00 respectively. These are explicit, reportable transactions that change the reporting person’s outstanding direct and derivative holdings and represent observable insider liquidity rather than an operational development for the issuer.
TL;DR Transactions were executed under a documented 10b5-1 plan and reported on Form 4, meeting standard disclosure practices.
The filer states the sales were effected pursuant to a 10b5-1 trading plan adopted 12/03/2024 and provides weighted average sale prices and ranges. The Form 4 includes an attorney-in-fact signature and required explanatory footnotes. From a governance and disclosure perspective the filing contains the expected details for insider option exercise and programmed sales.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 16,485 | $2.00 | $33K |
| Exercise | Stock Option | 100,000 | $0.00 | -- |
| Exercise | Common Stock | 100,000 | $0.67 | $67K |
| Sale | Common Stock | 183,515 | $1.9484 | $358K |
Footnotes (1)
- The reported transactions were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 3, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.8750 to $2.0200 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.0000 to $2.0010 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
